Trial · NCT02764801
Contrast-enhanced Ultrasound Evaluation of Chemoembolization
NCT02764801, Phase 3, Completed, Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; results first posted 2023-09-21
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Contrast-enhanced Ultrasound Evaluation of Chemoembolization. Trials, record NCT02764801. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02764801
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Contrast-enhanced Ultrasound Evaluation of Chemoembolization
- NCT number
- NCT02764801
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 131 participants, actual
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
- Conditions
- Hepatocellular Carcinoma, Chemoembolization, Therapeutic
- Interventions
- Ultrasound contrast agent (Contrast-enhanced ultrasound), Logiq E9 Scanner (Contrast-enhanced ultrasound)
- First posted
- 2016-05-06
- Last updated
- 2025-05-06
- Results first posted
- 2023-09-21
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Patients Correctly Identified as Requiring Tumor Re-treatment Two Weeks After Initial Chemoembolization | Percentage of patients correctly identified as requiring re-treatment will be identified 1-2 weeks after the subject's chemoembolization procedure | The ability of contrast-enhanced ultrasound to detect residual disease (and thereby need for tumor re-treatment) will be determined 1-2 weeks post chemoembolization. |
| Primary | Percentage of Patients Correctly Identified as Requiring Tumor Re-treatment One Month After Initial Chemoembolization | Percentage of patients correctly identified as requiring re-treatment will be identified 1 month after the subject's chemoembolization procedure | The ability of contrast-enhanced ultrasound to detect residual disease (and thereby need for tumor re-treatment) will be determined 1 month post chemoembolization. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Percentage of Patients Correctly Identified as Requiring Tumor Re-treatment Two Weeks After Initial Chemoembolization | Percentage of patients correctly identified as requiring re-treatment will be identified 1-2 weeks after the subject's chemoembolization procedure | percentage | NUMBER | |
| PRIMARY | Percentage of Patients Correctly Identified as Requiring Tumor Re-treatment One Month After Initial Chemoembolization | Percentage of patients correctly identified as requiring re-treatment will be identified 1 month after the subject's chemoembolization procedure | percentage | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Patients Correctly Identified as Requiring Tumor Re-treatment Two Weeks After Initial Chemoembolization | Contrast Ultrasound Arm | 94 | 95% Confidence Interval 88 to 97 | percentage | |
| Percentage of Patients Correctly Identified as Requiring Tumor Re-treatment One Month After Initial Chemoembolization | Contrast Ultrasound Arm | 91 | 95% Confidence Interval 84 to 95 | percentage |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Contrast Ultrasound Arm | 131 | |
| Overall Study | COMPLETED | Contrast Ultrasound Arm | 103 | |
| Overall Study | NOT COMPLETED | Contrast Ultrasound Arm | 28 |
Source ClinicalTrials.gov
Adverse events7
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | nausea/vomiting | Gastrointestinal disorders | Contrast Ultrasound Arm | 1 | 103 | 103 |
| other | IV infiltration | Product Issues | Contrast Ultrasound Arm | 1 | 103 | 103 |
| other | post-embolization syndrome | General disorders | Contrast Ultrasound Arm | 2 | 103 | 103 |
| serious | shortness of breath | Respiratory, thoracic and mediastinal disorders | Contrast Ultrasound Arm | 1 | 103 | 1 |
| serious | episodic atrial fibrillation | Cardiac disorders | Contrast Ultrasound Arm | 1 | 103 | 1 |
| serious | esophageal variceal bleeding | Respiratory, thoracic and mediastinal disorders | Contrast Ultrasound Arm | 1 | 103 | 1 |
| serious | late dyspnea | Respiratory, thoracic and mediastinal disorders | Contrast Ultrasound Arm | 1 | 103 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Contrast Ultrasound Arm | 35 | 103 |
| Total, other adverse events | Contrast Ultrasound Arm | 4 | 103 |
| Total, serious adverse events | Contrast Ultrasound Arm | 4 | 103 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01CA194307 | 2D and 3D Contrast-enhanced Ultrasound Evaluation of Chemoembolization. | EISENBREY, JOHN | THOMAS JEFFERSON UNIVERSITY | NATIONAL CANCER INSTITUTE | 2016 to 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02764801
GET https://conductscience.org/api/trials/v1/NCT02764801/registered